US Patent Issued to Ablynx, Merck Patent on Oct. 6 for "Aggrecan binding immunoglobulins" (Belgian, German Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,224, issued on Oct. 6, was assigned to Ablynx NV (Zwijnaarde, Belgium) and Merck Patent GmbH (Darmstadt, Germany).

"Aggrecan binding immunoglobulins" was invented by Soren Steffensen (Etterbeek, Belgium), Gerald Beste (Ghent, Belgium), Guy Hermans (Merelbeke, Belgium), Hans Guhring (Geisenheim, Germany), Christoph Ladel (Darmstadt, Germany) and Lars Toleikis (Kleinniedesheim, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions a...